Drug intelligence / Profile preview

BG18

Development stage: Preclinical
Lead developer: BioSTAR Group
Modality: Small Molecules

Overview

BG18 is a preclinical-stage investigational compound being developed by Beijing Biostar Pharmaceuticals for the treatment of solid tumors. It functions as a Protein phosphatase 2A (PP2A) inhibitor. PP2A is a ubiquitous serine/threonine phosphatase that plays a critical role in regulating the cell cycle, DNA replication, and various signal transduction pathways, including the Akt and MAPK pathways. By inhibiting PP2A, BG18 aims to modulate these pathways to exert anti-tumor effects. The drug is currently part of Biostar's early-stage pipeline alongside other oncology assets.

Targets

PP2A (Protein phosphatase 2A)

Beyond the preview

Go deeper on BG18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG18.

Explore the full profile